EU Bans 16 New Cosmetic Ingredients Under Omnibus Act IX and Omnibus Act 3

Brands selling into the EU are looking at another formulation review. On 8 July 2026 the European Commission notified the WTO of a draft update to Regulation (EC) No 1223/2009, informally known as Omnibus Act IX on CMRs and Omnibus Act 3 on Ingredients. Its starting point is Delegated Regulation (EU) 2025/1222, the 23rd Adaptation to Technological Progress, which reclassified a batch of substances as carcinogenic, mutagenic or toxic for reproduction; the draft also folds in SCCS safety opinions issued through 2025 and 2026.
Three annexes are affected: II (the banned-substances list), III (restricted substances) and V (preservatives).
Below is the substance-by-substance breakdown, with the compliance deadline for each.
Annex II: 16 substances added to the banned list
The draft adds 16 substances to Annex II, the EU’s list of ingredients prohibited in cosmetic products:
| # | Substance | CAS | Placing on the market* | Making available* |
|---|---|---|---|---|
| 1 | 2-ethylhexanoic acid, monoester with propane-1,2-diol | 85114-00-7 | 1 Feb 2027 | 1 Feb 2027 |
| 2 | a,a’-propylenedinitrilodi-o-cresol | 94-91-7 | 1 Feb 2027 | 1 Feb 2027 |
| 3 | Ozone | 10028-15-6 | 1 Feb 2027 | 1 Feb 2027 |
| 4 | Dinitrogen oxide | 10024-97-2 | 1 Feb 2027 | 1 Feb 2027 |
| 5 | 9-octadecenoic acid (Z)-, sulfonated, potassium salts and related reaction products | 68609-93-8, 67968-63-2 | 1 Feb 2027 | 1 Feb 2027 |
| 6 | 2,3-epoxypropyl isopropyl ether | 4016-14-2 | 1 Feb 2027 | 1 Feb 2027 |
| 7 | Tetrahydrofurfuryl methacrylate | 2455-24-5 | 1 Feb 2027 | 1 Feb 2027 |
| 8 | Trimethyl phosphate | 512-56-1 | 1 Feb 2027 | 1 Feb 2027 |
| 9 | Fluoroethylene | 75-02-5 | 1 Feb 2027 | 1 Feb 2027 |
| 10 | 2-bromo-3,3,3-trifluoroprop-1-ene | 1514-82-5 | 1 Feb 2027 | 1 Feb 2027 |
| 11 | 2-phenylpropene / a-methylstyrene | 98-83-9 | 1 Feb 2027 | 1 Feb 2027 |
| 12 | Benzophenone-1 | 131-56-6 | 12 months after entry into force | 24 months after entry into force |
| 13 | Benzophenone-2 | 131-55-5 | 12 months after entry into force | 24 months after entry into force |
| 14 | Basic Brown 16 | 26381-41-9 | 12 months after entry into force | 24 months after entry into force |
| 15 | Basic Blue 99 | 68123-13-7 | 12 months after entry into force | 24 months after entry into force |
| 16 | Prostaglandins and their analogues | – | 12 months after entry into force | 24 months after entry into force |
*These dates are not yet official. The amendment has only been notified to the WTO as a draft and has not been formally adopted or published, so the dates could still shift. Based on an expected adoption in late 2026, the 12/24-month transitions work out to an estimated late 2027/early 2028 (placing on the market) and late 2028/early 2029 (making available).
Benzophenone-1 and Benzophenone-2 are the ones most likely to affect formulators directly, since both have seen use as UV filters and photostabilisers in sunscreens and other leave-on products. Brands still relying on either should be lining up replacement filters now.
Annex III: Hydroxyapatite (nano), CBD, and BHA
The restriction on Hydroxyapatite (nano) under entry 372 is replaced outright. The maximum concentration rises to 29.5% in toothpaste and 10% in mouthwash, with the ban in every other product category staying in place. Nano forms also pick up tighter particle specifications: at least 87% of rod-shaped particles must have an aspect ratio of 3 or less (the remainder capped at 9), particles must be uncoated and unmodified, and maximum particle length is set at 122 ± 43 nm. Existing CPSRs referencing the old entry will need a review.
Two new entries are added:
| Ingredient | Allowed in | Max concentration | Condition | Placing on the market* | Making available* |
|---|---|---|---|---|---|
| Cannabidiol (CBD), CAS 13956-29-1 | Leave-on, rinse-off, oral care | 0.19% | THC impurity capped at 0.00025% (2.5 ppm) | 12 months after entry into force | 24 months after entry into force |
| Butylated Hydroxyanisole (BHA), CAS 25013-16-5 | Leave-on, rinse-off | 0.07% | Not permitted in oral care or in products that could expose the lungs by inhalation | 12 months after entry into force | 24 months after entry into force |
This is the first time CBD gets a defined concentration limit and purity threshold in Annex III rather than sitting in a regulatory grey zone, which should make formulating with it considerably more straightforward.
Annex V: Butylparaben split out, mercury preservatives phased out completely
Entry 12a currently covers Butylparaben. Under the draft, it and the new entry 12b are reshaped as follows:
| Entry | Substance(s) | Key limits | Placing on the market* | Making available* |
|---|---|---|---|---|
| 12a (replaced) | Propylparaben, sodium propylparaben, potassium propylparaben | 0.14% as acid (sum of individual concentrations); 0.8% as acid in mixtures with entries 12 and 12b, provided combined butyl- and propylparaben does not exceed 0.14%; banned in leave-on nappy-area products for children under three | No transition stated | No transition stated |
| 12b (new) | Butylparaben, sodium butylparaben, potassium butylparaben | Same general limits, plus a stricter regime for children under 10 (0.14% rinse-off, 0.002% leave-on, 0.092% oral care); banned in any sprayable product that could expose the lungs; same nappy-area warning for children under three | 12 months after entry into force | 24 months after entry into force |
| 16 & 17 (deleted) | Mercury-based preservatives (Thiomersal/Thimerosal, phenylmercuric salts) | Entries removed outright; the general mercury ban in Annex II is extended to cover every mercury-containing substance without exception | 12 months after entry into force | 24 months after entry into force |
*Dates for entry 12b and the deletion of entries 16 and 17 are not yet official, for the same reason noted above – the amendment is still a draft. Based on an expected adoption in late 2026, this works out to an estimated late 2027/early 2028 (placing on the market) and late 2028/early 2029 (making available).
When this takes effect
Two separate timelines apply, depending on how each change was introduced:
| Change | Deadline |
|---|---|
| The first 11 new Annex II entries and new Annex V entry 12b (tied to the CMR classifications in Delegated Regulation (EU) 2025/1222) | 1 February 2027 |
| All other new bans and restrictions – placing on the market | 12 months after the regulation enters into force |
| All other new bans and restrictions – making available on the market | 24 months after the regulation enters into force |
The placing-on-the-market and making-available split is the usual EU cosmetics pattern: the earlier date stops new stock from entering the market, the later one lets existing stock sell through.
What to do now
With the 1 February 2027 deadline already fixed for the CMR-linked changes, formulations containing any of the affected substances need to be reviewed and reformulated well ahead of that date, and CPSRs, PIFs and labelling updated to match.
CE.way can run an ingredient screen against this list for your current portfolio, flag any formulations at risk, and manage the CPSR and PIF updates once reformulation is confirmed. Get in touch at info@ceway.eu.
References
- European Commission, WTO Technical Barriers to Trade notification G/TBT/N/EU/1219 (8 July 2026): draft amending act (PDF)
- European Commission, TBT notification cover sheet G/TBT/N/EU/1219: notification details
- Council of the European Union, draft text ST 13462/2026 ADD 1: full annex amendments (PDF)
- Commission Delegated Regulation (EU) 2025/1222 of 2 April 2025 (23rd ATP to the CLP Regulation): EUR-Lex, Official Journal


